Five Benenfits of Tirzepatide No. 1 Search on Google

Five Benenfits of Tirzepatide No. 1 Search on Google -By Polypeptide.ltd

Authoritative source：PubChem Tirzepatide is a synthetic derivative that combines the functionalities of gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This unique combination enables Tirzepatide to effectively lower blood glucose levels, improve insulin sensitivity, promote feelings of satiety, and facilitate weight loss.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

Authoritative source：Nature ❶ Improved Glycemic Control. Tirzepatide helps regulate blood sugar levels in individuals with type 2 diabetes. It works by stimulating the release of insulin from pancreatic beta cells and inhibiting the release of glucagon, which helps to reduce the amount of glucose produced by the liver. By increasing insulin sensitivity and reducing glucose production, Tirzepatide can lead to improved glycemic control and lower HbA1c levels.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

Authoritative source：Thelancet ❷ Weight Loss. Tirzepatide has shown promise as a medication that can contribute to weight loss.

It acts on the GLP-1 receptor, which helps to slow down gastric emptying and promote feelings of fullness and satiety. These effects can lead to a reduced caloric intake and potential weight loss.

Clinical trials have demonstrated significant weight loss in individuals using Tirzepatide compared to those using a placebo or other diabetes medications. ❸ Cardiovascular Benefits. Tirzepatide has exhibited potential cardiovascular benefits beyond its effects on blood sugar control. Clinical trials have shown a potential reduction in the risk of major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular-related death.

These findings suggest that Tirzepatide may have additional protective effects on the cardiovascular system, making it a valuable option for individuals with type 2 diabetes at risk of cardiovascular complications. ❹ Combination Therapy. Tirzepatide can be used as a monotherapy or in combination with other diabetes medications, such as metformin or SGLT2 inhibitors. This flexibility allows healthcare providers to tailor treatment plans to the specific needs of each patient. Combination therapy with Tirzepatide can provide comprehensive glycemic control by addressing different aspects of glucose regulation. ❺ Single Weekly Injection. One of the advantages of Tirzepatide is its once-weekly dosing regimen. Unlike some other diabetes medications that require daily dosing, Tirzepatide can be administered once a week, providing convenience and potentially improving treatment adherence.

This simplified dosing schedule can make it easier for individuals to incorporate the medication into their routine.

Reference citations [1] Ahangarpour M, Kavianinia I, Harris PW, Brimble MA (January 2021). "Photo-induced radical thiol-ene chemistry: a versatile toolbox for peptide-based drug design". Chemical Society Reviews.

Royal Society of Chemistry.

50 (2): 898–944. doi:10.1039/d0cs00354a. PMID 33404559. S2CID 230783854.

[2] "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023.

Retrieved 22 January 2023. This article incorporates text from this source, which is in the public

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

domain.

[3] Jump up to:a b c d e f g h i j k l "Drug Trials Snapshots: Mounjaro". U.S. Food and Drug Administration (FDA). 13 June 2023. Retrieved 14 June 2023. This article incorporates text from this source, which is in the public domain.

[4] Dutta D, Surana V, Singla R, Aggarwal S, Sharma M (November–December 2021). "Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis". Indian Journal of Endocrinology and Metabolism. 25 (6): 475–489. doi:10.4103/ijem.ijem_423_21. PMC 8959203. PMID 35355921.

[5] Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. (4 June 2022). "Tirzepatide Once Weekly for the Treatment of Obesity". NEJM. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID 35658024. S2CID 249385412. Archived from the original on 5 June 2022. Retrieved 6 June 2022.

[6] "Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes". Business Insider. RTTNews. 19 October 2021. Archived from the original on 28 October 2021. Retrieved 28 October 2021.

[7] Kellaher, Colin (28 April 2022). "Eli Lilly's Tirzepatide Meets Main Endpoints in Phase 3 Obesity Study". MarketWatch. Dow Jones Newswires. Archived from the original on 29 April 2022.

Retrieved 29 April 2022.

[8] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.

(August 2021). "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes".

The New England Journal of Medicine.

385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647. S2CID 235635529.

[9] Dee, Jane E. (6 June 2022). "More Than 20% Weight Reduction in Individuals With Obesity". Yale Department of Internal Medicine. Archived from the original on 10 June 2022.

Retrieved 12 June 2022.

[10] Davis, Nicola (5 June 2022). "Diabetes drug leads to notable weight loss in people with obesity – study". The Guardian. Archived from the original on 11 June 2022. Retrieved 12 June 2022.

[11] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

[12] Jump up to:a b c "Mounjaro EPAR". European Medicines Agency (EMA). 18 July 2022. Archived from the original on 12 December 2022. Retrieved 2 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[13] Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G (November 2022).

"Tirzepatide: A Systematic Update".

Int J Mol Sci. 23 (23). doi:10.3390/ijms232314631. PMC 9741068. PMID 36498958.

[14] "Mounjaro: Pending EC decision". European Medicines Agency. 22 July 2022. Archived from the original on 28 July 2022. Retrieved 30 July 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[15] "Mounjaro Product information". Union Register of medicinal products. Archived from the original on 8 February 2023. Retrieved 3 March 2023.

[16] "Drug and Health Product Submissions Under Review (SUR): New drug submissions completed". Health Canada. 10 March 2021. Archived from the original on 5 January 2023.

Retrieved 5 January 2023.

[17] Jump up to:a b Min T, Bain SC (January 2021). "The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials". Diabetes Therapy. 12 (1): 143–157. doi:10.1007/s13300-020-00981-0. PMC 7843845. PMID 33325008.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/